MIRXES-B (02629) made a spectacular debut on the Hong Kong Stock Exchange, soaring 33.26% in early trading on Friday. The stock opened at HK$29 per share, representing a 24.5% premium over its initial public offering (IPO) price of HK$23.30.
Mirxes Holding, the parent company of MIRXES-B, successfully completed its IPO and began trading on the Hong Kong market. The strong opening suggests significant investor interest in the company, which likely specializes in biotechnology or medical research given its "-B" designation typically used for biotech firms listed in Hong Kong.
The impressive first-day performance of MIRXES-B reflects the ongoing appetite for innovative healthcare and biotech companies in the Asian markets. Investors appear optimistic about the company's prospects, driving the stock price substantially higher than its initial offering. As trading continues, market participants will be closely watching to see if the stock can maintain its strong momentum throughout its debut session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。